Developing a Comprehensive Platform for Identification of Synthetic Lethal Targets Using Patient-Derived Cells
Time: 12:30 pm
day: Conference Day Two
Details:
- Combining the scalability of high-throughput technologies with the unmatched precision and translational relevance of advanced primary models in Ryvu’s cutting-edge drug discovery platform
- Leveraging human stem cell-derived models, patient-derived xenografts (PDXs), and clinical samples to establish a groundbreaking approach in uncovering synthetic lethal (SL) targets uniquely tied to oncogenic pathways
- Using our proprietary ranking algorithm to identify and validate novel drug targets missed in conventional immortalized cell lines, overcoming limitations caused by genetic and epigenetic drift in long-term cell culture system
